
|Articles|September 23, 2015
Shaji Kumar on Later Lines of Treatment for Myeloma
Author(s)Shaji Kumar
There are several agents available for patients who experience recurrence, Kumar says, though nearly all of them have the potential to move to an earlier setting.
Advertisement
Shaji Kumar, professor of medicine, Division of Hematology, Mayo Clinic, provides an overview of later lines of therapy for patients with multiple myeloma.
There are several agents available for patients who experience recurrence, Kumar says, though nearly all of them have the potential to move to an earlier setting.
Advertisement
Advertisement
Advertisement
Trending on CURE
1
FDA Approves Enhertu Plus Perjeta in Advanced HER2+ Breast Cancer
2
FDA Grants Fast Track Status to Muzastotug for Some Colorectal Cancers
3
SHARON Trial Offers a Potential Approach for Advanced Pancreatic Cancer
4
FDA Grants Breakthrough Designation to INCA-33989 in Essential Thrombocythemia
5





